Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey

Authors: Jingbo Yu, Shreekant Parasuraman, Dilan Paranagama, Andrew Bai, Ahmad Naim, David Dubinski, Ruben Mesa

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Patients with the myeloproliferative neoplasms (MPNs) myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are at increased risk for thrombotic and cardiovascular events and experience a variety of burdensome symptoms. However, there is a paucity of data in the biomedical literature about how MPNs impact productivity in the workplace. This analysis of the Living with MPNs survey was conducted to evaluate the impact of MPNs on employment, career potential, and work productivity.

Methods

This cross-sectional online survey included respondents aged 18–70 years living in the United States with a diagnosis of MF, PV, or ET. The survey consisted of ~ 100 questions related to MPN diagnosis, disease-related medical history, MPN-related symptoms and functional status, changes in employment and work productivity, and impact on daily activities since diagnosis. The MPN Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) was used to assess symptom burden. The Work Productivity and Activity Impairment Specific Health Problem questionnaire (WPAI-SHP) was used to assess the effects of MPNs on work productivity and activity (7-day recall) among currently employed respondents. Correlations between MPN-SAF TSS and WPAI-SHP scores were calculated using Spearman’s coefficients.

Results

Of 904 respondents, 592 were employed (MF, n = 174; PV, n = 248; ET, n = 170) at the time of their MPN diagnosis. Approximately half (50.5%) of the 592 employed survey respondents reported ≥1 change in employment status because of their diagnosis, most commonly “left a job” (30.2%) “went on medical disability leave” (24.8%), and “had reductions in work hours for at least 3 months” (21.8%). Among respondents who remained employed at the time of survey participation (n = 398), mean WPAI-SHP scores were as follows: absenteeism, 6.9%; presenteeism, 27.4%; overall work impairment, 31.1%; and activity impairment, 32.8%. WPAI-SHP scores positively correlated with MPN-SAF TSS (correlation coefficients, 0.37–0.70; P < 0.001).

Conclusions

Half of the employed respondents had an employment status change (eg, leaving a job, medical disability leave, early retirement) because of their disease since the diagnosis. Currently employed respondents reported meaningful impairments in work productivity and activities of daily living that were attributable to their MPNs, and the degree of impairments highlighted the severity of symptom burden.
Appendix
Available only for authorised users
Literature
1.
go back to reference Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed
2.
go back to reference Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–103.CrossRefPubMedPubMedCentral Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–103.CrossRefPubMedPubMedCentral
3.
go back to reference Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN landmark survey. BMC Cancer. 2016;16:167.CrossRefPubMedPubMedCentral Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN landmark survey. BMC Cancer. 2016;16:167.CrossRefPubMedPubMedCentral
4.
go back to reference Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995–3001.CrossRefPubMedPubMedCentral Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995–3001.CrossRefPubMedPubMedCentral
5.
go back to reference Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55:595–600.CrossRefPubMed Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55:595–600.CrossRefPubMed
6.
go back to reference Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.CrossRefPubMed Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.CrossRefPubMed
8.
go back to reference Zajacova A, Dowd JB, Schoeni RF, Employment WRB. Income losses among cancer survivors: estimates from a national longitudinal survey of American families. Cancer. 2015;121:4425–32.CrossRefPubMedPubMedCentral Zajacova A, Dowd JB, Schoeni RF, Employment WRB. Income losses among cancer survivors: estimates from a national longitudinal survey of American families. Cancer. 2015;121:4425–32.CrossRefPubMedPubMedCentral
9.
go back to reference Yu J, Parasuraman S, Paranagama D, Naim A, Dubinski D, Bai A et al. Impact of myeloproliferative neoplasms on patients' employment status and work productivity in the united states: Results from the Living With MPN patient survey. Blood (ASH Annual Meeting Abstracts). 2016;128:abstract 4256. Yu J, Parasuraman S, Paranagama D, Naim A, Dubinski D, Bai A et al. Impact of myeloproliferative neoplasms on patients' employment status and work productivity in the united states: Results from the Living With MPN patient survey. Blood (ASH Annual Meeting Abstracts). 2016;128:abstract 4256.
11.
go back to reference Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353–65.CrossRefPubMed Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353–65.CrossRefPubMed
12.
go back to reference Tevaarwerk AJ, Lee JW, Terhaar A, Sesto ME, Smith ML, Cleeland CS, et al. Working after a metastatic cancer diagnosis: factors affecting employment in the metastatic setting from ECOG-ACRIN's symptom outcomes and practice patterns study. Cancer. 2016;122:438–46.CrossRefPubMed Tevaarwerk AJ, Lee JW, Terhaar A, Sesto ME, Smith ML, Cleeland CS, et al. Working after a metastatic cancer diagnosis: factors affecting employment in the metastatic setting from ECOG-ACRIN's symptom outcomes and practice patterns study. Cancer. 2016;122:438–46.CrossRefPubMed
13.
go back to reference Hone D, Cheng A, Watson C, Huang B, Bitman B, Huang XY, et al. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2013;65:1564–72. Hone D, Cheng A, Watson C, Huang B, Bitman B, Huang XY, et al. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2013;65:1564–72.
14.
go back to reference Jetha A, Chen C, Mustard C, Ibrahim S, Bielecky A, Beaton D, et al. Longitudinal examination of temporality in the association between chronic disease diagnosis and changes in work status and hours worked. Occup Environ Med. 2017;74:184–91.CrossRefPubMed Jetha A, Chen C, Mustard C, Ibrahim S, Bielecky A, Beaton D, et al. Longitudinal examination of temporality in the association between chronic disease diagnosis and changes in work status and hours worked. Occup Environ Med. 2017;74:184–91.CrossRefPubMed
15.
go back to reference Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, et al. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in central and Eastern Europe in the PRESERVE study. Clin Rheumatol. 2013;32:1275–81.CrossRefPubMed Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, et al. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in central and Eastern Europe in the PRESERVE study. Clin Rheumatol. 2013;32:1275–81.CrossRefPubMed
16.
go back to reference Allen-Ramey FC, Gupta S, DiBonaventura MD. Patient characteristics, treatment patterns, and health outcomes among COPD phenotypes. Int J Chron Obstruct Pulmon Dis. 2012;7:779–87.PubMedPubMedCentral Allen-Ramey FC, Gupta S, DiBonaventura MD. Patient characteristics, treatment patterns, and health outcomes among COPD phenotypes. Int J Chron Obstruct Pulmon Dis. 2012;7:779–87.PubMedPubMedCentral
17.
go back to reference Chen H, Blanc PD, Hayden ML, Bleecker ER, Chawla A, Lee JH, et al. Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health. 2008;11:231–9.CrossRefPubMed Chen H, Blanc PD, Hayden ML, Bleecker ER, Chawla A, Lee JH, et al. Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health. 2008;11:231–9.CrossRefPubMed
18.
go back to reference daCosta DiBonaventura M, Cappelleri JC, Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. Pain Med. 2011;12:118–26.CrossRefPubMed daCosta DiBonaventura M, Cappelleri JC, Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. Pain Med. 2011;12:118–26.CrossRefPubMed
19.
go back to reference Zirkzee EJM, Sneep AC, de Buck PD, Allaart CF, Peeters AJ, Ronday HK, et al. Sick leave and work disability in patients with early arthritis. Clin Rheumatol. 2008;27:11–9.CrossRefPubMed Zirkzee EJM, Sneep AC, de Buck PD, Allaart CF, Peeters AJ, Ronday HK, et al. Sick leave and work disability in patients with early arthritis. Clin Rheumatol. 2008;27:11–9.CrossRefPubMed
20.
go back to reference Johnson S, Davis M, Kaltenboeck A, Birnbaum H, Grubb E, Tarrants M, et al. Early retirement and income loss in patients with early and advanced Parkinson's disease. Appl Health Econ Health Policy. 2011;9:367–76.CrossRefPubMed Johnson S, Davis M, Kaltenboeck A, Birnbaum H, Grubb E, Tarrants M, et al. Early retirement and income loss in patients with early and advanced Parkinson's disease. Appl Health Econ Health Policy. 2011;9:367–76.CrossRefPubMed
23.
go back to reference Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol. 2017;96:1653–65.CrossRefPubMedPubMedCentral Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol. 2017;96:1653–65.CrossRefPubMedPubMedCentral
Metadata
Title
Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
Authors
Jingbo Yu
Shreekant Parasuraman
Dilan Paranagama
Andrew Bai
Ahmad Naim
David Dubinski
Ruben Mesa
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4322-9

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine